Prognostic Value of Circulating Tumoral Free DNA Versus Circulating Tumoral Cells in Patients With Colorectal Cancer Stage II-III

Plain-language summary

This study compares the prognostic value of circulating tumor-free DNA versus circulating tumor cells, measured through blood sampling, in patients with stage II-III colorectal cancer. Patients over 18 with histologically confirmed stage II or III colon or rectal cancer who have undergone curative surgery may take part. It was carried out as a study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

University Hospital, Rouen

Intervention

Blood sampling

Start date

10/15/2012

Estimated completion

6/3/2019

Countries

France

Related genes

Locations

• Rouen, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Male or female, age superior to 18 years.
* Histologically confirmed colonic or rectal adenocarcinoma.
* stage II or III (TNM classification).
* Curative resection (R0)
* Absence of metastasis (abdominal ultrasonography or CTscan and pulmonary Rx or CTscan) in exams performed within 4 weeks.
* ECOG performance status \<3.
* Signed and dated informed consent document.

Exclusion Criteria:

* Metastatic disease.
* Familial adenomatous polyposis
* Prior chemotherapy and or radiotherapy within 6 weeks
* Medical history of cancer within 5 years except: basocellular cutaneous neoplasia and intraepithelial neoplasia of the cervix